Three of the most common immunologic targets, prostate specific antigen, prostatic acid phosphatase, and prostate specific membrane antigen are highly expressed in nearly all prostate cancers with increasing expression in advanced stage disease and metastases30–32. Here, FOLH1 is linked to prostate carcinoma.